Adults w/ nosocomial pneumonia, community acquired pneumonia, or complicated skin & soft tissue infections that is known or suspected to be caused by susceptible gm +ve bacteria.
Reports of myelosuppression including anaemia, leucopenia, pancytopenia & thrombocytopenia; lactic acidosis; serotonin syndrome; peripheral & optic neuropathy & optic neuritis progressing to loss of vision; convulsions. Closely monitor blood counts in patients w/ preexisting anaemia, granulocytopenia or thrombocytopenia, severe renal insufficiency; those receiving concomitant medications that may decrease Hb levels, depress blood counts or adversely affect platelet count or function. Monitor CBC wkly regardless of baseline blood count. Use only in patients w/ known or possible co-infection w/ gm -ve organisms if there are no alternative treatment options available in complicated skin & soft tissue infections. Consider antibiotic-associated diarrhoea & colitis, including pseudomembranous colitis & Clostridium difficile-associated diarrhoea in patients who develop serious diarrhoea during or after use. Discontinue ongoing treatment & initiate adequate therapeutic measures immediately if antibiotic-associated diarrhoea or colitis is suspected or confirmed; drugs inhibiting peristalsis are contraindicated in this situation. Inhibits mitochondrial protein synthesis. Patients w/ history of seizures. Limited data when administered to patients w/ underlying conditions &/or on concomitant medications which might put them at risk from MAO inhibition; experience in patients w/ diabetic foot lesions, decubitus or ischaemic lesions, severe burns or gangrene. Take appropriate measures should superinfection occur during therapy. Safety & effectiveness when administered for periods >28 days have not been established. Warn patients about the potential for dizziness or symptoms of visual impairment while on treatment & advise not to drive or operate machinery if these symptoms occur. Use in patients w/ severe renal & hepatic insufficiency only when the anticipated benefit is considered to outweigh the theoretical risk. No experience in patients undergoing continuous ambulatory peritoneal dialysis or alternative treatments for renal failure. Not to be used during pregnancy unless clearly necessary. Discontinue breastfeeding prior to & throughout administration. Safety & efficacy has not been established in childn <18 yr. Greater risk of experiencing blood dyscrasias in elderly.
Sign Out
